Tao Wang

Dr. Tao Wang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
YZYing Zhang
Ying Zhang
MJMantang Jiang
Mantang Jiang
TWTao Wang
Tao Wang
Myocardial ischemia-reperfusion injury (MIRI) is a critical issue that arises when restoring blood flow after an ischemic event in the heart. Excessive reactive oxygen species (ROS) production during this process exacerbates cellular damage and impairs cardiac function. Recent therapeutic strategies have focused on leveraging the ROS microenvironment to design targeted drug delivery systems. ROS-responsive biomaterials have emerged as promising candidates, offering enhanced therapeutic efficacy with reduced systemic adverse effects. This review examines the mechanisms of ROS overproduction during myocardial ischemia-reperfusion and summarizes significant advancements in ROS-responsive biomaterials for MIRI treatment. We discuss various chemical strategies to impart ROS sensitivity to these materials, emphasizing ROS-induced solubility switches and degradation mechanisms. Additionally, we highlight various ROS-responsive therapeutic platforms, such as nanoparticles and hydrogels, and their unique advantages in drug delivery for MIRI. Preclinical studies demonstrating the efficacy of these materials in mitigating MIRI in animal models are reviewed, alongside their mechanisms of action and potential clinical implications. We also address the challenges and future prospects of translating these state of the art biomaterial-based therapeutics into clinical practice to improve MIRI management and cardiac outcomes. This review will provide valuable insights for researchers and clinicians working on novel therapeutic strategies for MIRI intervention.

Verified
Journal Article
Open access
PDF file
XLXiaojuan Li
Xiaojuan Li
TWTao Wang
Tao Wang
QZQilong Zhou
Qilong Zhou
FLFan Li
Fan Li
TLTing Liu
Ting Liu
WHWen Huang
Wen Huang
Severe acute pancreatitis (SAP), a widespread inflammatory condition impacting the abdomen with a high mortality rate, poses challenges due to its unclear pathogenesis and the absence of effective treatment options. Isorhamnetin (ISO), a naturally occurring flavonoid, demonstrates robust antioxidant and anti-inflammatory properties intricately linked to the modulation of mitochondrial function. However, the specific protective impact of ISO on SAP remains to be fully elucidated. In this study, we demonstrated that ISO treatment significantly alleviated pancreatic damage and reduced serum lipase and amylase levels in the mouse model of SAP induced by sodium taurocholate (STC) or L-arginine. Utilizing an in vitro SAP cell model, we found that ISO co-administration markedly prevented STC-induced pancreatic acinar cell necrosis, primarily by inhibiting mitochondrial ROS generation, preserving ATP production, maintaining mitochondrial membrane potential, and preventing the oxidative damage and release of mitochondrial DNA. Mechanistically, our investigation identified that high-temperature requirement A2 (HtrA2) may play a central regulatory role in mediating the protective effect of ISO on mitochondrial dysfunction in STC-injured acinar cells. Furthermore, through an integrated approach involving bioinformatics analysis, molecular docking analysis, and experimental validation, we uncovered that ISO may directly impede the histone demethylation activity of KDM5B, leading to the restoration of pancreatic HtrA2 expression and thereby preserving mitochondrial function in pancreatic acinar cells following STC treatment. In conclusion, this study not only sheds new light on the intricate molecular complexities associated with mitochondrial dysfunction during the progression of SAP but also underscores the promising value of ISO as a natural therapeutic option for SAP.

11 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YLYong Li
Yong Li
CZChufeng Zhang
Chufeng Zhang
DTDongmei Tang
Dongmei Tang
TWTao Wang
Tao Wang
WYWei Yan
Wei Yan
JYJianhong Yang
Jianhong Yang
For decades, microtubules—composed of αβ-tubulin dimers—have been primary targets for cancer chemotherapy. While eight binding sites on the tubulin dimer have been structurally characterized, this study reveals a ninth. We found that the tubulin inhibitor Tumabulin-1 (TM1, a BML284 derivative) binds simultaneously to the well-known colchicine site and a previously unknown site, designated as Tumabulin site. This site resides at the interface of α1-tubulin, β1-tubulin, and RB3 within the tubulin–RB3–tubulintyrosine ligase complex. Remarkably, two TM1 molecules bind cooperatively to this relatively large pocket, interacting with all three proteins. Crucially, this binding is dependent on RB3; it is absent when RB3 is missing or the key residue H71 is mutated (H71Q). We further designed and synthesized Tumabulin-2 (TM2) that selectively binds the Tumabulin site, excluding binding the colchicine site. TM2 acts as a molecular glue, strengthening the interaction between RB3 and the tubulin dimer and consequently enhancing RB3’s tubulin-depolymerizing activity. In conclusion, our findings confirm the existence of a ninth tubulin-binding site and offer a promising foundation for developing Tubulin–RB3 molecular glues as a next generation of anticancer therapeutics.

11 September 2022 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
TWTao Wang
Tao Wang
YXYing Xiao
Ying Xiao
JZJingyao Zhang
Jingyao Zhang
FJFujia Jing
Fujia Jing
GZGuodan Zeng
Guodan Zeng
Background: Hypoxia inducible factor-1 (HIF-1) plays a key role in modulating post-infarct healing after myocardial ischemic injury through transcriptional regulation of hundreds of genes involved in diverse cardiac remodeling processes. However, the dynamic changes in HIF-1 target gene expression in the ischemic heart after myocardial infarction (MI) have not been well characterized. Methods: We employed a rhesus monkey model of MI induced by left anterior descending artery ligation and examined the expression pattern of HIF-1 target genes in the ischemic heart at 1, 7, and 28 days after injury by bulk RNA-sequencing analysis. Results: Myocardial transcriptomic analysis demonstrated a temporal-specific regulation of genes associated with the inflammatory response, cell proliferation, fibrosis and mitochondrial metabolism during the pathological progression of MI. HIF-1 target genes involved in processes related to glycolysis, angiogenesis, and extracellular matrix (ECM) remodeling also exhibited distinct expression patterns during MI progression. Copper concentrations were gradually decreased in the heart after ischemic injury, which was positively correlated with the expression of HIF-1-mediated angiogenic and glycolytic genes but negatively correlated with the expression of HIF-1-mediated ECM remodeling genes. Moreover, genes related to intracellular copper trafficking and storage were suppressed along with the loss of myocardial copper in the ischemic heart. Conclusions: This study demonstrated a dynamic, functional-specific regulation of HIF-1 target gene expression during the progression of MI. The fine-tuning of HIF-1 signaling in the ischemic heart may be relate to the alteration in myocardial copper homeostasis. These findings provide transcriptomic insights into the distinct roles of HIF-1 signaling in the heart after ischemic injury, which will help determine the beneficial cutoff point for HIF-1 targeted therapy in ischemic heart diseases.

21 October 2025 in World Journal of Gastroenterology
Verified
Journal Article
Open access
XZXi-Yue Zhang
Xi-Yue Zhang
MHMeng-Di Hu
Meng-Di Hu
DMDiliare Maimaitijiang
Diliare Maimaitijiang
TWTao Wang
Tao Wang
LWLin Wang
Lin Wang
Pancreatitis poses persistent diagnostic and therapeutic challenges due to its heterogeneous clinical presentation, variable disease course, and lack of targeted interventions. Conventional tools, such as serum enzymes, cross-sectional imaging and clinical scoring systems, often exhibit limited sensitivity and prognostic value, especially during early or atypical stages. Moreover, therapeutic development remains slow, with limited progress toward personalized or mechanism-based strategies. These limitations highlight a critical need for integrative data-driven approaches. Artificial intelligence (AI) has emerged as a promising tool to enhance clinical decision-making in pancreatitis. This narrative review synthesizes recent progress in AI applications across three domains. First, AI-enabled diagnostic platforms incorporating radiomics, deep learning-based imaging analysis, and biomarker optimization have improved early detection and differentiation of pancreatic diseases. Second, AI-driven prognostic models now allow real-time severity prediction, complication forecasting, and recurrence risk assessment, some of which have been deployed in hospital information systems for intensive care units and mortality risk triage. Third, AI-assisted drug discovery and network pharmacology, particularly in combination with traditional Chinese medicine, have revealed novel therapeutic opportunities. Despite encouraging developments, challenges remain in data standardization, model transparency and clinical validation. A multidisciplinary strategy integrating omics data, longitudinal monitoring and pharmacological modeling may help bridge current gaps and advance precision medicine in pancreatitis care.

Verified
Journal Article
Open access
PDF file
QWQiuling Wu
Qiuling Wu
QZQilong Zhou
Qilong Zhou
CWChengyu Wan
Chengyu Wan
GXGuang Xin
Guang Xin
TWTao Wang
Tao Wang
WHWen Huang
Wen Huang
Renovascular hypertension (RH), a secondary hypertension, can significantly impact heart health, resulting in heart damage and dysfunction, thereby elevating the risk of cardiovascular diseases. Coniferol (CA), which has vascular relaxation properties, is expected to be able to treat hypertension-related diseases. However, its potential effects on cardiac function after RH remain unclear. In this study, in combination with network pharmacology, the antihypertensive and cardioprotective effects of CA in a two-kidney, one-clip (2K1C) mice model and its ability to mitigate angiotensin II (Ang II)-induced hypertrophy in H9C2 cells were investigated. The findings revealed that CA effectively reduced blood pressure, myocardial tissue damage, and inflammation after RH. The possible targets of CA for RH treatment were screened by network pharmacology. The interleukin-17 (IL-17) and tumor necrosis factor (TNF) signaling pathways were identified using a Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. The inflammatory response was identified using a Gene Ontology (GO) enrichment analysis. Western blot analysis confirmed that CA reduced the expression of IL-17, matrix metallopeptidase 9 (MMP9), cyclooxygenase 2 (COX2), and TNF α in heart tissues and the H9C2 cells. In summary, CA inhibited cardiac inflammation and fibrohypertrophy following RH. This effect was closely linked to the expression of MMP9/COX2/TNF α/IL-17. This study sheds light on the therapeutic potential of CA for treating RH-induced myocardial hypertrophy and provides insights into its underlying mechanisms, positioning CA as a promising candidate for future drug development.